Research programme: heat shock protein 90 modulators - Evotec AG/Genextra

Drug Profile

Research programme: heat shock protein 90 modulators - Evotec AG/Genextra

Alternative Names: HSP90-targeted compounds - Evotec/Genextra

Latest Information Update: 07 Jul 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Evotec AG; Genextra
  • Class Small molecules
  • Mechanism of Action Heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 07 Jul 2009 Discontinued - Preclinical for Cancer in Germany (unspecified route)
  • 07 Jul 2009 Discontinued - Preclinical for Cancer in Italy (unspecified route)
  • 07 Jul 2009 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top